ArticleFrontiers in veterinary science2026
BVDV utilizes PGC-1α downregulation to remodel the mitochondrial metabolic microenvironment, enhancing viral replication and impairing host immunity.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bovine viral diarrhea virus (BVDV) is a major pathogen affecting global livestock production, and virus-induced mitochondrial remodeling is closely associated with viral replication. However, the role of PGC-1α-mediated mitochondrial quality control in cytopathic BVDV strain NADL infection remains unclear. Methods: MDBK cells were infected with CP BVDV(NADL) to establish an in vitro infection model. Mitochondrial morphology, function, mitophagy levels, and the expression of related proteins were examined using transmission electron microscopy, fluorescence staining, confocal microscopy, Western blotting, and the pADV-CMV-FH-cox8-EGFP-mCherry vector dual-fluorescence system. PGC-1α expression was manipulated by plasmid-mediated overexpression or shRNA-mediated knockdown.Viral replication was quantified by qRT-PCR, and IFN-β secretion was assessed by ELISA. Results: CP BVDV(NADL) infection caused mitochondrial structural damage and dysfunction, accompanied by persistent downregulation of PGC-1α and its downstream target TFAM. Meanwhile, Drp1 expression was increased, shifting mitochondrial dynamics toward excessive fission. CP BVDV(NADL) infection also markedly enhanced PINK1-mediated mitophagy. Functionally, PGC-1α overexpression restored mitochondrial homeostasis, inhibited PINK1-dependent mitophagy, reduced IFN-β expression, and ultimately suppressed CP BVDV(NADL) replication. Conversely, PGC-1α interference further promoted mitophagy and increased mPTP opening. Discussion: These findings demonstrate for the first time that CP BVDV(NADL) promotes viral replication by manipulating PGC-1α-mediated mitochondrial quality control. This mechanism reveals a novel metabolic strategy used by BVDV and provides potential therapeutic targets for controlling CP BVDV(NADL) infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.